World of DTC Marketing

APRIL 12, 2021

The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. The answer lies in both an outdated way we develop prescription drugs and the continued quest for the next big blockbuster. In other words, money over safety.

Food and Drug Administration 187

Food and Drug Administration Prescription Pharma Manufacturing 187

PM360

NOVEMBER 14, 2023

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went into effect in May. The price is available to cash-paying patients with a valid prescription. for only $35. References: 1.

Retail 52

Retail Pharmaceutical manufacturing Sales Insurance 52

PM360

AUGUST 9, 2022

One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. Unlike other formulary optimization solutions, Levrx delivers plan-specific and real-time prescription insights. billion in 2030 at a CAGR of 9.2%.

Prescription 105

Prescription Medical Side effects Patients 105

European Pharmaceutical Review

NOVEMBER 8, 2022

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

PM360

DECEMBER 20, 2023

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. In 2021, the out-of-pocket (OOP) cost accounts for 28% of the whole healthcare expenses compared to 15.4% billion people in 2023).

Marketing 105

Marketing Insurance Medical Manufacturing 105

pharmaphorum

OCTOBER 27, 2022

The Guidance will act as a non-binding and evolving resource for companies and provide additional clarification about communications with healthcare professionals (HCPs), healthcare organisations (HCOs), patient organisations (POs), and other stakeholders, including the general public.

Media 92

Media Pharmaceutical Medicine Electronics 92

Clarify Health

OCTOBER 26, 2021

With the myriad of guidance and recommendations to boost diversity and inclusion in oncology trials, , biotech and pharmaceutical manufacturers are left to interpret the criteria and implement them through tangible action. Clarify launched its real-world evidence on health disparities in 2021.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52